Melanoma Perspective

• ACMS 2022 Read clinically focused news coverage of key developments from ACMS 2022.
  Medscape Dermatology, May 13, 2022
• Oncogene-Positive Lung Cancer: What Therapy to Start?   Dr Mark Kris discusses the choice between chemotherapy and targeted therapy in patients with lung cancer and oncogenic drivers.
  Medscape Oncology, April 20, 2022
  2
• When Physicians Are the Plaintiffs The view from the exam table may not be as rosy as we hope when we are patients. Can we fix that?
  Medscape Blogs, February 25, 2022
  18
• ESMO 2021 Melanoma Update: 3 Important Trials from ESMO 2021   Dr Jeffrey Weber discusses recent melanoma studies presented at ESMO 2021.
  Medscape Oncology, December 22, 2021
• Noise in Medicine "Both bias and noise create trouble for us. Although biases get more attention, noise is both more prevalent and insidious," Jeffrey Benabio, MD, MBA, says in his column.
  Medscape Dermatology, September 30, 2021
• ASCO 2021 New Long-term Melanoma Data 'Clearly Favor' IPI/NIVO   Dr Jeffrey Weber discusses long-term follow-up data presented at ASCO 2021.
  Medscape Oncology, August 03, 2021
• Our Immunocompromised Patients Need a Third Dose Three physicians who specialize in the treatment of immunocompromised patients make the case for a third dose of COVID-19 vaccine.
  Medscape Oncology, July 30, 2021
  12
• ASCO 2021 What's Next After Anti-PD-1 Therapy for Melanoma Fails?   Dr Jeffrey Weber describes two studies with encouraging results for patients with advanced melanoma that has not responded to anti-PD-1 and other immunotherapies.
  Medscape Oncology, July 29, 2021
• ASCO 2021 NIVO + LAG-3 Antibody Succeeds in Advanced Melanoma   ASCO studies validate dual LAG-3 and PD-1 inhibition in advanced melanoma, with good tolerability profiles, says Jeffrey Weber.
  Medscape Oncology, July 01, 2021
• Melanoma Highlights From ASCO 2021   From ASCO 2021, Dr Jeffrey Weber reviews key data on melanoma, including results of new immunotherapy agent relatlimab in combination with nivolumab, and 5-year overall survival from the COLUMBUS trial.
  Medscape, June 29, 2021
• Success for a New Type of Checkpoint Inhibitor Promising results in a study of >700 treatment-naive advanced melanoma patients.
  Medscape Blogs, June 18, 2021
• TMB Is Not a Universal Predictive Biomarker   A compelling new study shows why we should not rush to consider tumor mutational burden a pan-tumor predictive marker.
  Medscape Oncology, May 18, 2021
• ACMS 2021 Read clinically focused news coverage of key developments from  ACMS 2021.
  Medscape Dermatology, May 14, 2021
• Studies Back Neoadjuvant Strategies for Melanoma   Two analyses of neoadjuvant immunotherapy support more rigorous study with RCTs of neoadjuvant vs adjuvant strategies for melanoma, says Dr Weber.
  Medscape Oncology, March 24, 2021
• Medscape at 25: Recognizing Medicine's Rising Stars For Medscape's 25th anniversary, we're recognizing 25 young physicians who are rising stars in medicine, poised to become future leaders of their fields.
  Medscape, December 07, 2020
  29
• Breakthroughs in Melanoma From ESMO Virtual Congress 2020   Highlights in melanoma from ESMO 2020 include first-line treatment sequencing, prediction of long-term survival, and a novel combination therapy after progression, as discussed by Dr Caroline Robert.
  Medscape, October 12, 2020
• Malpractice Case: Being Passive About Referrals Can Be Risky Overlooking key steps in the patient hand-off can lead to missing information and trigger treatment mishaps.
  Cooperative of American Physicians, October 05, 2020
  33
• 'Impressive Results' From Stage III Melanoma Studies: ASCO 2020   Dr Jeffrey Weber describes three adjuvant and/or neoadjuvant studies in stage III melanoma that piqued his interest at this year's American Society of Clinical Oncology virtual meeting.
  Medscape Oncology, August 25, 2020
• Re-treating Melanoma After PD-1 Blockade Shows Good Response   In patients who received single-agent PD-1 blockade for melanoma, how effective is second-line therapy? A recent study addresses this important question.
  Medscape Oncology, July 22, 2020
• Searching for Biomarkers to Better Guide Melanoma Therapy   Dr Jeffrey Weber explores the phase 3 COMBI-AD melanoma trial. Could tumor mutational burden alone or in combination with interferon gamma gene signature be a prognostic factor?
  Medscape Oncology, June 03, 2020